Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index
Viracta Therapeutics, Inc. (Nasdaq: VIRX) has been selected for addition to the Nasdaq Biotechnology Index (NBI), effective December 20, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viracta Therapeutics, Inc. (Nasdaq: VIRX) has been selected for addition to the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. The NBI tracks biotechnology and pharmaceutical securities on the Nasdaq and is re-ranked annually through a modified capitalization-weighted methodology. Viracta focuses on precision oncology targeting virus-associated malignancies, with its investigational drug nanatinostat currently in trials for EBV-positive lymphoma and nasopharyngeal carcinoma.
Positive
- Inclusion in the Nasdaq Biotechnology Index may enhance visibility and attract institutional investors.
- Ongoing clinical trials for nanatinostat position the company in a growing sector of precision oncology targeting EBV-related cancers.
Negative
- None.
Details
News Market Reaction – VIRX
The recorded move for VIRX in the trading session of this news was +2.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.
The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NBI is re-ranked each year and is calculated under a modified capitalization-weighted methodology. Additionally, the NBI forms the basis for a number of Exchange Traded Funds (ETFs). More information about the NBI, including eligibility criteria, can be found at https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a registration-enabling Phase 2 clinical trial for EBV-positive (EBV+) lymphoma and a Phase 1b/2 trial in patients with EBV+ nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-be-added-to-the-nasdaq-biotechnology-index-301445981.html
SOURCE Viracta Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.